Some studies have demonstrated that the absence of hENT1 as assessed by immunohistochemistry in tumor tissue was associated with shortened survival in gemcitabine-treated patients with PDA and have proposed hENT1 expression as a prognostic biomarker for gemcitabine sensitivity (27). The gene discussed is SLC29A1; the disease is neoplasm.